Innovation
Artificial intelligence has arrived in aesthetic medicine — and like most transformative technologies, it has arrived unevenly. Alongside genuinely impressive clinical tools, there is considerable noise: overhyped products, premature claims, and a great deal of confusion about what AI can actually do in a clinical setting today versus what it might do in five years.
This piece is an attempt at clarity. Not a breathless endorsement of AI as the future of everything, nor a dismissive scepticism that misses what is genuinely changing. A clear-eyed assessment of where the technology is delivering real value, where it is falling short, and what practitioners should actually be paying attention to.
The most compelling current applications of AI in aesthetics are in diagnostics and treatment planning. AI-powered skin analysis tools — using computer vision to assess skin texture, pigmentation, pore size, and other parameters — have reached a level of accuracy that is genuinely useful in clinical practice. They provide objective, reproducible measurements that support more precise treatment recommendations and allow practitioners to track outcomes over time in ways that were previously impractical.
Facial analysis tools that use AI to model treatment outcomes — showing patients a simulation of how they might look after a procedure — are also maturing rapidly. When used responsibly, these tools can improve consultation quality, manage patient expectations, and support more informed consent. The key word is responsibly: simulations that overpromise outcomes create the conditions for patient dissatisfaction.
The most important thing AI cannot do is replace clinical judgement. It can inform it, support it, and augment it — but the decision remains with the practitioner.
The aesthetics market has a long history of adopting technologies before the evidence base is fully established. AI is no exception. Several categories of AI-powered products are currently being marketed with claims that significantly outpace the clinical evidence supporting them.
Diagnostic tools that claim to identify conditions or predict treatment responses without peer-reviewed validation should be approached with caution.
AI-generated treatment plans that are not reviewed and contextualised by a qualified practitioner create clinical and medico-legal risk.
Patient communication tools that use AI to respond to clinical queries without appropriate oversight can undermine trust and create liability.
Outcome simulation tools that present idealised results rather than realistic ranges set expectations that clinical reality cannot meet.
Beyond diagnostics, there are several areas where AI is already delivering practical value for clinic operations. AI-powered scheduling and patient communication tools can reduce administrative burden significantly. Predictive analytics tools can help identify patients at risk of churning, or flag those most likely to respond to specific treatment recommendations. Content generation tools can support marketing teams in producing consistent, on-brand communication at scale.
The most important thing AI cannot do is replace clinical judgement. It can inform it, support it, and augment it — but the decision about what to do, and how to do it, remains with the practitioner. The clinics that will benefit most from AI are those that use it to enhance their clinical and operational capabilities, not those that use it to replace the human expertise that patients are actually paying for.
Continue Reading
Back to The Journal